Everolimus eluting bioresorbable vascular scaffolds; can we absorb the risk in complex PCI?
Sign Up to like & getrecommendations! Published in 2017 at "Catheterization and Cardiovascular Interventions"
DOI: 10.1002/ccd.27165
Abstract: Key Points BVS, as compared with DES, have higher stent thrombosis (ST) rates. BVS may prove reasonable in patients with complex anatomy. Future trials will be necessary to guide clinicians regarding whether BVS are equivalent… read more here.
Keywords: vascular scaffolds; anatomy; everolimus eluting; eluting bioresorbable ... See more keywords
First‐in‐man study of a thinner‐strut sirolimus‐eluting bioresorbable scaffold (FUTURE‐I): Three‐year clinical and imaging outcomes
Sign Up to like & getrecommendations! Published in 2020 at "Catheterization and Cardiovascular Interventions"
DOI: 10.1002/ccd.28722
Abstract: The FUTURE‐I study aimed to assess preliminary safety and effectiveness with the long‐term clinical and imaging follow‐up for the Firesorb (MicroPort, Shanghai, China), a thinner‐strut sirolimus‐eluting bioresorbable scaffold (BRS). read more here.
Keywords: strut sirolimus; thinner strut; bioresorbable scaffold; sirolimus eluting ... See more keywords
Diabetes and everolimus eluting bioresorbable poly‐L‐lactide vascular scaffolds for coronary artery disease: Dead‐end or some path forward?
Sign Up to like & getrecommendations! Published in 2021 at "Catheterization and Cardiovascular Interventions"
DOI: 10.1002/ccd.29900
Abstract: • Bioresorbable vascular scaffolds (BVS) intend to overcome long-term limitations of permanent metallic coronary stent implants, particularly in the proinflammatory, prothrombotic diabetic milieu. • The Amsterdam Investigator-Initiated Absorb Strategy All-Comers (AIDA) trial demonstrates worse 3year… read more here.
Keywords: diabetes everolimus; poly lactide; everolimus eluting; eluting bioresorbable ... See more keywords
Everolimus-eluting bioresorbable vascular scaffold in daily clinical practice: A single-centre experience
Sign Up to like & getrecommendations! Published in 2017 at "Netherlands Heart Journal"
DOI: 10.1007/s12471-017-1038-4
Abstract: BackgroundRecent evidence has raised concerns regarding the safety of the everolimus-eluting bioresorbable vascular scaffold (E-BVS) (Absorb, Abbott Vascular, Santa Clara, CA, USA). Following these data, the use of this device has diminished in the Netherlands;… read more here.
Keywords: vascular scaffold; centre; practice; everolimus eluting ... See more keywords
A new novolimus-eluting bioresorbable coronary scaffold: Present status and future clinical perspectives.
Sign Up to like & getrecommendations! Published in 2017 at "International journal of cardiology"
DOI: 10.1016/j.ijcard.2016.11.033
Abstract: The DESolve® scaffold (Elixir Medical Corporation, Sunnyvale, California, USA) is manufactured from a poly-l-lactide based polymer and elutes an anti-proliferative, anti-inflammatory drug, Novolimus from a poly-l-lactide based topcoat mixture. The strut thickness is 150μm and… read more here.
Keywords: new novolimus; bioresorbable coronary; coronary scaffold; novolimus eluting ... See more keywords
Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of the American College of Cardiology"
DOI: 10.1016/j.jacc.2017.04.011
Abstract: BACKGROUND Recent evidence suggests that bioresorbable vascular scaffolds (BVS) are associated with an excess of thrombotic complications compared with metallic everolimus-eluting stents (EES). OBJECTIVES This study sought to investigate the comparative effectiveness of the Food and Drug… read more here.
Keywords: risk; compared metallic; metallic ees; bioresorbable scaffolds ... See more keywords
TCT-11 Everolimus-Eluting Bioresorbable Scaffolds Versus Drug-Eluting Stents in Patients With Acute Myocardial Infarction: 2-Year Results of the Randomized ISAR-Absorb MI Trial
Sign Up to like & getrecommendations! Published in 2019 at "Journal of the American College of Cardiology"
DOI: 10.1016/j.jacc.2019.08.034
Abstract: Present data revealed higher event rates in patients who underwent everolimus-eluting bioresorbable scaffold (BRS) implantation compared with patients treated with metallic drug-eluting stents (DES). Of these studies, only 1 randomized trial is available, which addresses… read more here.
Keywords: trial; drug eluting; eluting stents; everolimus eluting ... See more keywords